| Clinical BRCA1/2 Reversion Analysis Identifies Hotspot Mutations and Predicted Neoantigens Associated with Therapy Resistance SJ Pettitt, JR Frankum, M Punta, S Lise, J Alexander, Y Chen, TA Yap, ... Cancer discovery 10 (10), 1475-1488, 2020 | 112 | 2020 |
| Modelling mutational landscapes of human cancers in vitro M Olivier, A Weninger, M Ardin, H Huskova, X Castells, MP Vallée, ... Scientific reports 4 (1), 4482, 2014 | 99 | 2014 |
| Low rates of mutation in clinical grade human pluripotent stem cells under different culture conditions O Thompson, F von Meyenn, Z Hewitt, J Alexander, A Wood, ... Nature communications 11 (1), 1528, 2020 | 77 | 2020 |
| 17q21. 31 duplication causes prominent tau-related dementia with increased MAPT expression K Le Guennec, O Quenez, G Nicolas, D Wallon, S Rousseau, AC Richard, ... Molecular Psychiatry 22 (8), 1119-1125, 2017 | 71 | 2017 |
| Meta-analysis of Tourette Syndrome and Attention Deficit Hyperactivity Disorder provides support for a shared genetic basis F Tsetsos, SS Padmanabhuni, J Alexander, I Karagiannidis, M Tsifintaris, ... Frontiers in Neuroscience, 2016 | 40 | 2016 |
| Impairment of a distinct cancer-associated fibroblast population limits tumour growth and metastasis U Jungwirth, A van Weverwijk, RJ Evans, L Jenkins, D Vicente, ... Nature Communications 12 (1), 3516, 2021 | 39 | 2021 |
| Targeted re-sequencing approach of candidate genes implicates rare potentially functional variants in Tourette syndrome etiology J Alexander, H Potamianou, J Xing, L Deng, I Karagiannidis, F Tsetsos, ... Frontiers in neuroscience 10, 428, 2016 | 30 | 2016 |
| TS-EUROTRAIN: a European-wide investigation and training network on the etiology and pathophysiology of Gilles de la Tourette syndrome NJ Forde, AS Kanaan, J Widomska, SS Padmanabhuni, E Nespoli, ... Frontiers in neuroscience 10, 384, 2016 | 25 | 2016 |
| Predicting the clinical outcome of oral potentially malignant disorders using transcriptomic-based molecular pathology HP Sathasivam, R Kist, P Sloan, P Thomson, M Nugent, J Alexander, ... British Journal of Cancer 125 (3), 413-421, 2021 | 22 | 2021 |
| Variant Ranker: a web-tool to rank genomic data according to functional significance J Alexander, D Mantzaris, M Georgitsi, P Drineas, P Paschou BMC bioinformatics 18, 1-9, 2017 | 20 | 2017 |
| Familial early-onset dementia with complex neuropathologic phenotype and genomic background J Alexander, O Kalev, S Mehrabian, L Traykov, M Raycheva, D Kanakis, ... Neurobiology of Aging 42, 199-204, 2016 | 18 | 2016 |
| The genetics of Gilles de la Tourette syndrome: a common aetiological basis with comorbid disorders? I Karagiannidis, F Tsetsos, SS Padmanabhuni, J Alexander, M Georgitsi, ... Current Behavioral Neuroscience Reports 3, 218-231, 2016 | 15 | 2016 |
| ELTD1 activation induces an endothelial-EMT transition to a myofibroblast phenotype H Sheldon, J Alexander, E Bridges, L Moreira, S Reilly, KH Ang, D Wang, ... International Journal of Molecular Sciences 22 (20), 11293, 2021 | 9 | 2021 |
| The mutational concordance of fixed formalin paraffin embedded and fresh frozen gastro-oesophageal tumours using whole exome sequencing IY Chong, N Starling, A Rust, J Alexander, L Aronson, ... Journal of Clinical Medicine 10 (2), 215, 2021 | 7 | 2021 |
| SMG8/SMG9 heterodimer loss modulates SMG1 kinase to drive ATR inhibitor resistance MJ Llorca-Cardenosa, LI Aronson, DB Krastev, J Nieminuszczy, ... Cancer Research 82 (21), 3962-3973, 2022 | 6 | 2022 |
| Assessment of the molecular heterogeneity of E-cadherin expression in invasive lobular breast cancer J Alexander, O Mariani, C Meaudre, L Fuhrmann, H Xiao, K Naidoo, ... Cancers 14 (2), 295, 2022 | 5 | 2022 |
| Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency I Bajrami, C Walker, DB Krastev, D Weekes, F Song, AJ Wicks, ... Communications biology 4 (1), 1270, 2021 | 5 | 2021 |
| Longitudinal profiling identifies co-occurring BRCA1/2 reversions, TP53BP1, RIF1 and PAXIP1 mutations in PARP inhibitor resistant advanced breast cancer E Harvey-Jones, M Raghunandan, L Robbez-Masson, L Magraner-Pardo, ... Annals of Oncology, 2024 | 4 | 2024 |
| MND1 and PSMC3IP control PARP inhibitor sensitivity in mitotic cells A Zelceski, P Francica, L Lingg, M Mutlu, C Stok, M Liptay, J Alexander, ... Cell reports 42 (5), 2023 | 2 | 2023 |
| Targeting Transcriptional Regulation with a CDK9 Inhibitor Suppresses Growth of Endocrine- and Palbociclib-Resistant ER+ Breast Cancers A Soosainathan, M Iravani, R El-Botty, J Alexander, L Sourd, L Morisset, ... Cancer Research 84 (1), 17-25, 2024 | 1 | 2024 |
Syed HaiderThe Institute of Cancer Research, London在 icr.ac.uk 的电子邮件经过验证
